The ESTRO Scientific Council is pleased to relay this international survey on stereotactic radiotherapy for oligoprogressive cancer, led by Canadian colleagues. If you treat patients with SABR/SBRT, your insights matter!
We are a team of radiation oncologists in Canada who are conducting an international survey on practice patterns in the use of stereotactic radiotherapy for oligoprogressive cancer. We would very much appreciate your completion of this survey, if you treat patients in your clinical practice with stereotactic ablative radiotherapy (SABR)/ stereotactic body radiotherapy (SBRT).
The survey can be accessed here.
The deadline to participate in the survey is 29 February 2024.
Due to current lack of evidence to guide practice, institutions differ with respect to patient selection for SABR, prescription dose, and equipoise between SABR and other treatment approaches. Published results from the survey will provide an overview of international practice patterns in oligoprogressive cancer, and will also help with the design of a randomized clinical trial evaluating the benefit of SABR in this setting.
This survey consists of 23 questions and takes approximately 15 minutes to complete.
If you have any questions about the study, please contact the research lead Dr. Sarah Baker (firstname.lastname@example.org).
Thank you in advance for your help.
Sarah Baker, MD PhD
BC Cancer Surrey (BC, Canada)
Assistant Professor, University of British Columbia